Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy

Supportive Care in Cancer

Volumn 20, Issue 3, 2012, Pages 615-623

  Feinberg, Bruce ^a   Gilmore, James ^a   Haislip, Sally ^a   Jackson, James ^b   Jain, Gagan ^b   Balu, Sanjeev ^c   Buchner, Deborah ^c  

^a Georgia Cancer Specialists   (United States)

^b Eisai Inc ^*  (United States)

^c EISAI INC   (United States)

Author keywords

Antiemetic prophylaxis; CINV; Multi day chemotherapy; Ondansetron; Palonosetron

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; ONDANSETRON; PALONOSETRON;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 84857647136     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1140-x     Document Type: Article

References (45)

1. M de Boer-Dennert R de Wit PI Schmitz J Djontono V v Beurden G Stoter J Verweij 1997 Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists Br J Cancer 76 1055 1061 9376266 10.1038/bjc.1997.507 (Pubitemid 27434663)
2. B Bloechl-Daum RR Deuson P Mavros M Hansen J Herrstedt 2006 Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment J Clin Oncol 24 4472 4478 16983116 10.1200/JCO.2006.05.6382 1:CAS:528:DC%2BD28XhtVyisrrL (Pubitemid 46630986)
3. CM Lindley JD Hirsch CV O'Neill MC Transau CS Gilbert JT Osterhaus 1992 Quality of life consequences of chemotherapy-induced emesis Qual Life Res 1 331 340 1299465 10.1007/BF00434947 1:STN:280:DyaK3s3jtVajsw%3D%3D
4. BA Feinberg J Gilmore S Haislip T Gondesen MN Saleh W Hawke lenz 2009 Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting Comm Oncol 6 62 67
5. A Ihbe-Heffinger B Ehlken R Bernard K Berger C Peschel HG Eichler R Deuson J Thödtmann F Lordick 2004 The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers Ann Oncol 15 526 536 14998860 10.1093/annonc/mdh110 1:STN:280:DC%2BD2c7gvVertg%3D%3D (Pubitemid 38444561)
6. Y-CT Shih Y Xu LS Etling 2007 Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy Cancer 110 678 685 10.1002/cncr.22823 (Pubitemid 47106159)
7. PJ Hesketh 2008 Chemotherapy-induced nausea and vomiting N Engl J Med 358 2482 2494 18525044 10.1056/NEJMra0706547 1:CAS:528:DC%2BD1cXmvFKltL0%3D (Pubitemid 351793021)
8. K Jordan C Sippel HJ Schmoll 2007 Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations Oncologist 12 1143 1150 17914084 10.1634/theoncologist.12-9-1143 1:CAS:528:DC%2BD2sXht1Krs7rO (Pubitemid 350007026)
9. LS Schwartzberg 2007 Chemotherapy-induced nausea and vomiting: clinician and patient perspectives J Support Oncol 5 2 Suppl 1 5 12 17366928 1:CAS:528:DC%2BD2sXivF2rtr0%3D (Pubitemid 46344212)
10. MS Aapro 2007 Palonosetron as an anti-emetic and anti-nausea agent in oncology Ther Clin Risk Manag 3 1009 1020 18516316
11. RM Navari 2007 Prevention of emesis from multiple-day and high-dose chemotherapy regimens J Natl Compr Canc Netw 5 51 59 17239326 1:CAS:528:DC%2BD1cXmtFygsr8%3D (Pubitemid 46212277)
12. P Eisenberg FR MacKintosh P Ritch PA Cornett A Macciocchi 2004 Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study Ann Oncol 15 330 337 14760130 10.1093/annonc/mdh047 1:STN:280:DC%2BD2c%2FlvValtw%3D%3D (Pubitemid 38262636)
13. C Ruhlmann J Herrstedt 2010 Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting Expert Rev Anticancer Ther 10 137 148 20131990 10.1586/era.09.175 1:CAS:528:DC%2BC3cXhsFGitLg%3D
14. M Saito M Tsukuda 2010 Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting Expert Opin Pharmacother 11 1003 1014 20307224 10.1517/14656561003705746 1:CAS:528:DC%2BC3cXjvVehsLc%3D
15. MS Aapro SM Grunberg GM Manikhas G Olivares T Suarez SA Tjulandin LF Bertoli F Yunus B Morrica F Lordick A Macciocchi 2006 A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann Oncol 17 1441 1449 16766588 10.1093/annonc/mdl137 1:STN:280:DC%2BD28rktVensw%3D%3D (Pubitemid 44400384)
16. M Aapro A Fabi F Nolè M Medici G Steger C Bachmann S Roncoroni F Roila 2010 Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy Ann Oncol 21 1083 1088 20080830 10.1093/annonc/mdp584 1:STN:280:DC%2BC3c3pt1Sguw%3D%3D
17. P Eisenberg J Figueroa-Vadillo R Zamora V Charu J Hajdenberg A Cartmell A Macciocchi S Grunberg 99-04 Palonosetron Study Group 2003 Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2473 2482 14635083 10.1002/cncr.11817 1:CAS:528:DC%2BD3sXpvFOrt70%3D (Pubitemid 37466663)
18. LH Einhorn MJ Brames R Dreicer CR Nichols MT Cullen Jr J Bubalo 2007 Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer Support Care Cancer 15 1293 1300 17436025 10.1007/s00520-007-0255-6 (Pubitemid 47583451)
19. R Gralla M Lichinitser S Van Der Vegt H Sleeboom J Mezger C Peschel G Tonini R Labianca A Macciocchi M Aapro 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577 14504060 10.1093/annonc/mdg417 1:STN:280:DC%2BD3svktlKitQ%3D%3D (Pubitemid 37304615)
20. T Grote J Hajdenberg A Cartmell S Ferguson A Ginkel V Charu 2006 Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant J Support Oncol 4 403 408 17004515 1:CAS:528:DC%2BD28XhtVKntr7L (Pubitemid 44541016)
21. SM Grunberg M Dugan H Muss M Wood S Burdette-Radoux T Weisberg M Siebel 2009 Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy Support Care Cancer 17 589 594 19037667 10.1007/s00520-008-0535-9
22. J Hajdenberg T Grote L Yee R Arevalo-Araujo LA Latimer 2006 Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting J Support Oncol 4 467 471 17080735 1:CAS:528: DC%2BD28Xht1Wjt7fE (Pubitemid 44698155)
23. JD Herrington AD Jaskiewicz J Song 2008 Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting Cancer 112 2080 2087 18327813 10.1002/cncr.23364 1:CAS:528:DC%2BD1cXmtFOlu7s%3D (Pubitemid 351574085)
24. V Lorusso A Spedicato L Petrucelli V Saracino M Giampaglia T Perrone 2009 Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results Support Care Cancer 17 1469 1473 19294429 10.1007/s00520-009-0611-9 1:STN:280:DC%2BD1MjltVGgug%3D%3D
25. M Maemondo N Masuda I Sekine K Kubota Y Segawa M Shibuya F Imamura N Katakami T Hida S Takeo PALO Japanese Cooperative Study Group 2009 A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann Oncol 20 1860 1866 19561037 10.1093/annonc/mdp195 1:STN:280:DC%2BD1MjhvVCisg%3D%3D
26. E Massa G Astara C Madeddu M Dessì C Loi S Lepori G Mantovani 2009 Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response Crit Rev Oncol Hematol 70 83 91 18723369 10.1016/j.critrevonc. 2008.07.002
27. RM Navari LH Einhorn PJ Loehrer Sr SD Passik J Vinson J McClean N Chowhan NH Hanna CS Johnson 2007 A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study Support Care Cancer 15 1285 1291 17375339 10.1007/s00520-007-0248-5 (Pubitemid 47583449)
28. P Rzepecki W Pielichowski S Oborska J Barzal B Mlot 2009 Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience Transplant Proc 41 3247 3249 19857722 10.1016/j.transproceed.2009.07.071 1:CAS:528:DC%2BD1MXhtlWisbbK
29. M Saito K Aogi I Sekine H Yoshizawa Y Yanagita H Sakai K Inoue C Kitagawa T Ogura S Mitsuhashi 2009 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial Lancet Oncol 10 115 124 19135415 10.1016/S1470-2045(08)70313-9 1:CAS:528: DC%2BD1MXhtlGlurk%3D
30. W Tian Z Wang J Zhou S Zhang J Wang Q Chen C Huang L Pan L Zhang J Huang H Shen T Lin 2011 Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population Med Oncol 28 1 71 78 20049561 10.1007/s12032-009-9398-2 1:CAS:528:DC%2BC3MXisV2hu70%3D
31. Z Yu W Liu L Wang H Liang Y Huang X Si H Zhang D Liu H Zhang 2009 The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial Support Care Cancer 17 99 102 18825421 10.1007/s00520-008-0503-4
32. C Rojas M Stathis AG Thomas EB Massuda J Alt J Zhang E Rubenstein S Sebastiani S Cantoreggi SH Snyder B Slusher 2008 Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor Anesth Analg 107 469 478 18633025 10.1213/ane.0b013e318172fa74 1:CAS:528:DC%2BD1cXoslGktrc%3D Erratum in: Anesth Analg 2008;107:1405
33. C Rojas AG Thomas J Alt M Stathis J Zhang EB Rubenstein S Sebastiani S Cantoreggi BS Slusher 2010 Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function Eur J Pharmacol 626 193 199 19836386 10.1016/j.ejphar.2009.10.002 1:CAS:528: DC%2BD1MXhsV2mtLvO
34. Li Y, Wu X, Rojas C, Cantoreggi S, Sebastiani S, Slusher B (2009) Palonosetron uniquely inhibits substance P-mediated neuronal responses in rat no dose ganglia. Blood (ASH Annual Meeting Abstracts) 114:abstr 4826
35. Mattiuzzi G, Cortes J, McCue D, Bekele BN, Xiao L, Borthakur G, Kantarjian H (2009) Palonosetron (PALO) given daily for up to 5 days is significantly better than ondansetron (ONDA) in the prevention of delayed CINV in patients (pts) with acute myelogenous leukemia (AML). Blood (ASH Annual Meeting Abstracts) 114:abstr 993
36. Giralt S, Mangan K, Maziarz R, Bubalo JS, Beveridge R, Hurd DD, Mendoza F, Rubenstein EB, DeGroot TJ, Schuster MW (2008) Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT). J Clin Oncol 26(May 20 suppl):abstr 9617
37. J Homsi AY Bedikian KB Kim NE Papadopoulos W Hwu S Mahoney AG Vardeleon M Davies P Hwu 2009 Randomized trial of two schedules of palonosetron for the prevention of nausea and vomiting in patients with metastatic melanoma receiving interleukin-2-based concurrent biochemotherapy J Clin Oncol 27 15S e20008
38. LH Einhorn B Rapoport J Koeller SM Grunberg P Feyer C Rittenberg M Aapro 2005 Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement Support Care Cancer 13 112 116 15480812 10.1007/s00520-004-0704-4 (Pubitemid 40558167)
39. E Ellebaek J Herrstedt 2008 Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy Curr Opin Support Palliat Care 2 28 34 18685391 10.1097/SPC.0b013e3282f44a75
40. American Society of Clinical Oncology MG Kris PJ Hesketh MR Somerfield P Feyer R Clark-Snow JM Koeller GR Morrow LW Chinnery MJ Chesney RJ Gralla SM Grunberg 2006 American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932 2947 16717289 10.1200/JCO.2006.06. 9591 1:CAS:528:DC%2BD28XntV2gs7k%3D Erratum in: J Clin Oncol 2006;24:5341-5342 (Pubitemid 46630595)
41. National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in Oncology. Antiemesis. V.1.2010. http://nccn.org. Accessed April 7, 2010
42. F Roila J Herrstedt M Aapro RJ Gralla LH Einhorn E Ballatori E Bria RA Clark-Snow BT Espersen P Feyer SM Grunberg PJ Hesketh K Jordan MG Kris E Maranzano A Molassiotis G Morrow I Olver BL Rapoport C Rittenberg M Saito M Tonato D Warr ESMO/MASCC Guidelines Working Group 2010 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann Oncol 21 Suppl 5 v232 v243 20555089 10.1093/annonc/mdq194
43. A Billio E Morello MJ Clarke 2010 Serotonin receptor antagonists for highly emetogenic chemotherapy in adults Cochrane Database Syst Rev 1 CD006272 20091591
44. GM Decker ES DeMeyer DL Kisko 2006 Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy J Support Oncol 4 35-41 52
45. RM Navari 2009 Antiemetic control: toward a new standard of care for emetogenic chemotherapy Expert Opin Pharmacother 10 629 644 19284365 10.1517/14656560902731894 1:CAS:528:DC%2BD1MXjtF2mur4%3D